US Patent

US11819480 — Methods for treating cancer

Method of Use · Assigned to Radius Pharmaceuticals Inc · Expires 2037-02-28 · 11y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

Methods are disclosed for treating cancer by administering a therapeutically effective amount of RAD1901 to a subject with a drug-resistant or mutant estrogen receptor alpha positive cancer.

USPTO Abstract

Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant estrogen receptor alpha positive cancer or a mutant estrogen receptor alpha positive cancer. The methods entail administering to the subject a therapeutically effective amount of RAD1901 having the structure:or a salt or solvate thereof.

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3523`	—	elacestrant-hydrochloride
`U-3523`	—	elacestrant-hydrochloride

Patent Metadata

Patent number: US11819480
Jurisdiction: US
Classification: Method of Use
Expires: 2037-02-28
Drug substance claim: No
Drug product claim: No
Assignee: Radius Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.